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Genomic catastrophes frequently arise
in esophageal adenocarcinoma and drive
tumorigenesis
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Kelly A. Lofﬂer3, Suzanne Manning1, Senel Idrisoglu1, David Miller1, Qinying Xu1,2, Nick Waddell1, Peter J. Wilson1,
Timothy J.C. Bruxner1, Angelika N. Christ1, Ivon Harliwong1, Craig Nourse1, Ehsan Nourbakhsh1,
Matthew Anderson1, Stephen Kazakoff1, Conrad Leonard1,2, Scott Wood1,2, Peter T. Simpson2,5,6, Lynne E. Reid2,5,
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Oesophageal adenocarcinoma (EAC) incidence is rapidly increasing in Western countries.
A better understanding of EAC underpins efforts to improve early detection and treatment
outcomes. While large EAC exome sequencing efforts to date have found recurrent loss-of-
function mutations, oncogenic driving events have been underrepresented. Here we use a
combination of whole-genome sequencing (WGS) and single-nucleotide polymorphism-array
proﬁling to show that genomic catastrophes are frequent in EAC, with almost a third (32%,
n¼40/123) undergoing chromothriptic events. WGS of 22 EAC cases show that cata-
strophes may lead to oncogene ampliﬁcation through chromothripsis-derived double-minute
chromosome formation (MYC and MDM2) or breakage-fusion-bridge (KRAS, MDM2
and RFC3). Telomere shortening is more prominent in EACs bearing localized complex
rearrangements. Mutational signature analysis also conﬁrms that extreme genomic instability
in EAC can be driven by somatic BRCA2 mutations. These ﬁndings suggest that genomic
catastrophes have a signiﬁcant role in the malignant transformation of EAC.
DOI: 10.1038/ncomms6224 OPEN
1 Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia.
2 QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland 4006, Australia. 3 Surgical Oncology Group, School of Medicine, The University
of Queensland, Translational Research Institute at the Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia. 4 Department of
Anatomical Pathology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia. 5 The University of Queensland, UQ Centre for
Clinical Research, Herston, Brisbane, Queensland 4029, Australia. 6 The University of Queensland, School of Medicine, Herston, Queensland 4006, Australia.
7 Flinders University Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia 5042, Australia. 8 St Vincent’s Centre for Applied Medical
Research, University of Notre Dame and University of New South Wales, Sydney, New South Wales 2011, Australia. 9 Cancer Research Division, Peter
MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. 10 Department of Surgery, School of Medicine, The University of Queensland, Princess
Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia. 11 Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton,
Cambridgeshire CB10 1SA, UK. 12Wolfson Wohl Cancer Research Centre, Institute for Cancer Sciences, University of Glasgow, Garscube Estate, Switchback
Road, Bearsden, Glasgow G61 1BD, UK. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to
S.M.G. (email: Sean.Grimmond@glasgow.ac.uk) or to A.P.B. (email: a.barbour@uq.edu.au).
NATURE COMMUNICATIONS | 5:5224 | DOI: 10.1038/ncomms6224 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
O
esophageal adenocarcinoma (EAC) has one of the
poorest outcomes of all solid tumours, with only 14%
of patients surviving 5 years1. Surgery remains the main
curative treatment but it is only suitable forB50% of patients due
to the majority of EAC patients being diagnosed at an advanced
stage of the disease2. Large-scale genomic studies, predominantly
involving exome sequencing recently identiﬁed 26 genes
signiﬁcantly mutated in EAC3,4. Curiously, these genes were
affected by widespread of loss-of-function mutations in tumour
suppressors (TP53, ARID1A, SMAD4) whereas no obvious
oncogenic mutations linked to EAC progression were identiﬁed.
The most signiﬁcant risk factor for EAC is Barrett’s oesophagus
(BE), a pre-malignant lesion that progresses into EAC in 5–10%
of cases2. EACs can arise rapidly in patients diagnosed with BE,
even in those under careful surveillance. It is currently believed
that transformation of non-dysplastic BE to dysplastic BE and
then on to cancer is driven by a stepwise accumulation of
mutations but Weaver et al.4 showed that the majority of
recurrently mutated genes in EAC can also be found in non-
dysplastic BEs that did not progress towards cancer. Only the
tumour suppressor genes TP53 and SMAD4 have been shown to
occur in a disease stage speciﬁc manner but these were unable to
differentiate high-grade dysplastic BE from EAC. Taken together,
these data suggest that oncogenic events underlying EAC
progression are still at large.
While the mechanisms underlying EAC transformation are
poorly understood, both telomere shortening and copy number
alterations (CNAs) have been previously implicated5–8. Telomere
shortening was observed in BE at all histologic grades9 and was
associated with an increased risk of developing EAC10. Li et al.2 in
a longitudinal study of BE-EAC progression showed that the
genomes of BE that progress to EAC acquire signiﬁcant increase
of gain and losses with genomic diversity within 4 years of EAC
diagnosis suggesting that a rapid genomic evolution may underlie
the rapid EAC progression.
The present study addresses what role genomic rearrangements
have in promoting EAC. A combination of WGS, single-
nucleotide polymorphism (SNP) arrays and copy number
analysis conﬁrms that EACs have highly mutated and rearranged
genomes3,11 and surprisingly that chromothripsis and breakage-
fusion-bridge are frequent events in this cancer. Furthermore,
these genomic catastrophes may underlie mechanisms of
ampliﬁcation of potent oncogenes through the formation of
double-minute chromosomes and focal ampliﬁcations caused by
breakage-fusion-bridge (BFB). Finally, this study suggests possible
mechanisms for the rapid somatic genomic evolution that is a
characteristic of this disease.
Results
Somatic mutations in EAC. In an effort to summarize the
complete repertoire of somatic damage accumulated in EAC, a
discovery cohort of 22 fresh-frozen EAC and matched normal
tissues from EAC patients (all untreated before surgery) under-
went WGS. The clinical features of the cohort disease were typical
for EAC and are summarized in Supplementary Data 1. Analysis
using qpure tool12 conﬁrmed a median tumour cellularity of 73%
and deep WGS was performed at an average base pair depth
of 74-fold for tumour and 39-fold for normal samples
(Supplementary Data 2). Somatic substitutions were identiﬁed
using a dual-tool strategy using GATK13 and qSNP14, while
indels were identiﬁed using Pindel15. Re-sequencing of one
tumour/normal pair conﬁrmed the accuracy of substitution calls
to be 98.8%. Indels in coding regions were independently veriﬁed
by amplicon deep sequencing, conﬁrming 95% of the indels tested
(Supplementary Data 3). CNA analysis was performed on
high-density arrays using genome alteration print (GAP)16.
Structural variants (SVs) were detected using the qSV tool. SV
events were considered veriﬁed if presenting multiple lines of
evidence in the WGS data and/or supported by boundaries of
CNAs detected by SNP arrays, conﬁrming 69% of the events
(Supplementary Data 4).
Across the cohort, a total of 648,838 somatic SNVs and indels
were identiﬁed. The median mutational burden genome-wide was
8.0 mutations/Mb (range of 1.53–34.56) (Supplementary Data 2
and 3). In coding regions, a total of 4,412 SNVs and indels were
identiﬁed representing a median of seven mutations/Mb. These
values are similar to previous reports3,11 placing EAC as one of
the most mutated cancers along with bladder, colorectal, lung and
melanoma11. In total, 434 genes harboured non-silent mutations
in two or more patients (Supplementary Data 5). The overall
mutation pattern closely resembled those previously reported by
recent EAC exome sequencing efforts3,4, with 19 of the 26
signiﬁcantly mutated EAC genes3 mutated in the present cohort
(Supplementary Data 5). Copy number analysis identiﬁed 173
and 37 genes with recurrent gain or loss, respectively
(Supplementary Data 6), many of which have been previously
reported ampliﬁed (CCNE1 (n¼ 7), ERBB2 (n¼ 5), FRS2 (n¼ 4),
GATA4 (n¼ 4), KRAS (n¼ 6), MTMR9 (n¼ 6) and MDM2
(n¼ 3)) or lost (CDKN2A (n¼ 17), FHIT (n¼ 8) and RUNX1
(n¼ 13)) in EAC5,6.
Mutational processes active in EAC. Mutation spectral analysis
conﬁrmed that EACs display a preponderance of C4T transi-
tions in coding sequences and T4G transversions across the
genome3,17 (Supplementary Data 7). The sequence context of
mutations can reveal mutational processes or signatures within
tumours11. Three recently reported EAC mutational signatures11
were also detected here: Age signature (driven by general
deamination), APOBEC signature and T4G mutations at TT
sites. In addition, the BRCA-deﬁciency signature previously
reported only in breast, ovarian and pancreatic tumours11 and an
unknown signature were also observed (Fig. 1a). The signature
characterized by T4G mutations at TT sites was the most
prominent process within the cohort (Fig. 1b) and tumours with
high contribution of this signature showed a trend towards poor
survival (Supplementary Fig. 1). Strand bias was observed only for
the signature characterized by T4G mutations at TT sites
(Supplementary Fig. 2). T4G mutations at TT sites have been
proposed to arise from oxidative DNA damage3. Reﬂux of gastric
and bile acids which are risk factors for BE and EAC, have been
associated with oxidative stress and oxidative DNA damage18.
Furthermore incubation of BE tissues with a low pH bile acid
cocktail leads to increased formation of 8-OH-dG18, which was
suggested to be associated with T4G mutations at TT sites19,20.
This might indicate a mechanism underlying this mutational
signature that needs further investigation.
Localized hypermutation (kataegis) characterized by clusters of
C4T and C4G mutations on the same strand21, was described
here for the ﬁrst time in EAC, with four tumours possessing
numerous (Z10) kataegic foci (Supplementary Fig. 3) and 15
other EACs displaying occasional (o10 foci) kataegic regions
(Supplementary Data 8). Consistent with previous studies
implicating APOBEC proteins in kataegis21,22, the tumour with
the highest number of kataegic regions (n¼ 17; OESO_1154) also
had the highest contribution of the APOBEC signature (Fig. 1b).
Subtyping of EAC using structural rearrangement patterns. SV
analysis conﬁrmed that EAC genomes are complex and highly-
rearranged. A total of 7,343 SVs were identiﬁed (median of 263
SVs per tumour, range 126–776) (Supplementary Data 2 and 4).
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Many of these SV events were predicted to cause a loss-of-
function by disrupting coding sequence of 2,984 genes; 642 of
which were disrupted in two or more tumours (Supplementary
Data 4 and 9). A screen for gene fusion events across the cohort
identiﬁed 159 in-frame unique fusion genes (Supplementary
Data 4). This rate of fusion gene formation was similar to what is
expected by chance and is considered unlikely to drive cancer
biology23.
The genomic distribution of SVs revealed considerable
intertumour heterogeneity, enabling the categorization of the
cohort into: unstable genomes (tumours with Z450 SVs, n¼ 6),
scattered (o450 SV events evenly distributed across the genome,
n¼ 2) and complex localized (with a concentration of SVs in a
single or few chromosomes, n¼ 14; Supplementary Fig. 4).
Tumour OESO_1636 displayed an unstable genome (776 SVs)
and harboured a somatic nonsense BRCA2 mutation. The
pathogenicity of this event was supported by a prominent BRCA
mutational signature in this tumour (Fig. 1), suggesting an
underlying mechanism previously implicated in genomic
instability in other cancer types24.
Genomic catastrophes in EAC. Chromothripsis has been
reported in different cancer types25–28 and was initially thought
to be present in 2 to 3% of tumours25. Zack et al.29 detected
chromothripsis in 5% of tumours across 10 cancer types, ranging
from 0 to 16%, however, higher frequency has been reported in
bone cancer (25%)25 and medulloblastoma (36%)27. The
prevalence of chromothripsis in cancer genomes has been
recently reviewed by Kloosterman et al.30 This catastrophic
event is a plausible explanation for the concentration of SVs in
one or few chromosomes observed in EACs with complex
T>G mutations at TT sites
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Figure 1 | Mutational signatures found in EAC. (a) Five mutational signatures were detected in EAC. Each signature is represented by the proportion
of somatic substitutions (C4A, C4G, C4T, T4A, T4C and T4G). Substitutions are displayed in a trinucleotide context (including information
about the bases immediately 30 and 50 to the mutated base) resulting in 96 potential contexts. (b) Contribution of mutational signatures operative in
individual tumours. Each bar represents a tumour and the y axis represents the contribution of each signature within tumours, shown as number of
mutations per Mb. The BRCA, the unknown and APOBEC signatures were most prevalent only in one tumour each (BRCA contributed B57% of
OESO_1636 mutations and unknown signature represents 67% of OESO_0303 mutations). The APOBEC signature, previously described in EAC and other
tumour types11, contributes to more than 50% of the mutations in tumour OESO_1154, with small contributions in other samples. The age signature,
previously described in EAC, is the second major operative mutational processes in this cohort. The signature characterized by T4G at TTsites is the most
prominent within this cohort, representing Z40% of mutations in 10 of 22 tumours (Supplementary Fig. 1).
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localized genomes. Mitotic chromosome segregation errors that
lead to chromosome shattering (chromothripsis)25,31 can affect
several genes in only a few cell cycles and have the potential to
drive cancer development25. Such events may represent an
alternative mechanism to the stepwise accumulation of mutations
that lead to malignant transformation. Surprisingly, eight of the
22 EACs (36%) in the discovery cohort contained rearrangements
similar to chromothripsis (Figs 2–4, Supplementary Figs 5 and 6,
Supplementary Data 10 and 11). This high frequency of
chromothripsis was conﬁrmed by screening a further 101 EACs
using SNP arrays, with 32 out of 101 (32%) tumours showing
Z10 transitions between 2 or 3 copy number states, with loss and
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Figure 2 | Evidence of chromothripsis in EAC tumours. (a) Circos plot of tumour OESO_1527 containing copy number and BAF in the outer rings
and somatic structural variants (SVs) are represented by lines in the inner ring. Colour of the lines represents SV type as indicated in the legend. Circos
plot37 shows a high concentration of SVs on chromosome 9. (b) Zoomed-in view of events on chromosome 9 of tumour OESO_1527 showing evidence
of chromosome shattering (chromothripsis). From top to bottom, graphs show SVs, copy number, logR ratio and BAF. There are changes in copy
number state, concentration of a high number of SVs and retention of heterozygosity. (c) The genome distribution of somatic SVs for tumour OESO_3213.
Circos plot containing copy number and SVs shows a concentration of events on chromosome 8. (d) Zoomed-in view of events on chromosome 8 in
OESO_3213 showing SVs, copy number, logR ratio and B-allele frequency. (e) Inferred double-minute chromosome (DM) harbouring MYC oncogene. Blue
blocks show fragments of chromosome 8 inferred to form DM and green block shows position of FISH probe. (f) Agarose gel showing PCR veriﬁcation of
SV events inferred to contribute to the DM. T, tumour, N, adjacent normal esophagus, numbers indicate SVs as shown in e. (g) FISH conﬁrms copy
number alterations in d by showing MYC ampliﬁcation as multiple scattered signals and two copies of the chromosome 8 in a representative tumour cell
nucleus. (Green—ﬂuorescently labelled BAC RP11-367L7—MYC gene region; Red—centromeric region of chromosome 8—CHR8-10-RE). Scale bar, 10mm.
Supplementary Figures 11 and 12 are full images of gel and FISH presented in (f) and (g), respectively.
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preservation of heterozygosity in one or few chromosomes
(Supplementary Fig. 7). In total, 40 EACs out of 123 tumours
(32.5%) showed evidence of chromothripsis.
It has been previously shown that a potential by-product of
chromothripsis is the formation of double-minute chromosomes
(DM)25,27. DMs may harbour oncogenes and if providing a
competitive advantage to the cancer cells may be selected for
further ampliﬁcation during cell cycles resulting in a potential
oncogenic event. Evidence of this driving mechanism was
observed in half (n¼ 4) of the EACs with evidence of
chromothripsis, these tumours showed high copy number of
retained DNA fragments and SV events randomly connecting
those regions of high copy number.
The tumour OESO_3213 has evidence of a 2.5Mb DM derived
from shattering of chromosome 8 and random fusion of six
fragments; one of which harbours the MYC oncogene. The SV
events inferred to be involved in the DM were validated by PCR.
FISH analysis conﬁrmed that gene ampliﬁcation is not due to
homogenously staining regions but extra chromosomal ampliﬁ-
cation of MYC gene (Fig. 2). In a second tumour (OESO_0384),
evidence of DM arising from a chromothriptic event involving
four chromosomes harboured MDM2 gene was identiﬁed and
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similarly veriﬁed using PCR and FISH (Fig. 3). MDM2 is an
oncogene and known inhibitor of TP53.
In the discovery cohort of 22 EAC, six tumours displayed
localized genomic damage consistent with BFB events (Fig. 4,
Supplementary Fig. 8). BFB is known to begin with telomere loss,
followed by fusion of unprotected chromosomal ends or sister
chromatids fusion. These fused chromosomes are subsequently
torn apart during anaphase. This process can be repeated for
several cell cycles resulting in inverted duplications with dramatic
copy number increases, and when such ampliﬁed regions harbour
oncogenes, this may provide growth advantage to tumour cells.
Regions ampliﬁed by BFB cycles in the discovery cohort harbour
oncogenes or genes that promote tumour growth such as RCF3,
MDM2, VEGFA, BCAT1 and KRAS. Tumours with complex
localized SVs in their genomes showed higher prevalence of
inversions and deletions (Po0.05, t-test), with breakpoints
presenting a high incidence of microhomology, suggesting
microhomology-mediated break repair and/or non-homologous
recombination as the major mechanism of DNA repair
(Supplementary Fig. 9). WGS-based telomere integrity analysis
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found somatic telomere shortening in EAC, with tumours
displaying complex localize rearrangements presenting a more
prominent shortening (Supplementary Fig. 10).
Three EAC tumours showed evidence of both BFB and
chromothripsis events (Supplementary Fig. 10). Dicentric chro-
mosome formation by telomeric erosion has been suggested as a
potential mechanism leading to chromothripsis as an extreme
outcome of a mutagenesis mechanism31. Tumour OESO_3845
showed evidence of both BFB and chromothripsis (Fig. 4).
Chromosome 12 showed a high concentration of SVs suggesting a
series of BFB cycles between sister chromatids, with loss of the p
arm telomeric region and 20 inversions mapped to a small
ampliﬁed interval (Fig. 4). Approximately 30 genes are located in
this ampliﬁed region, including the oncogene KRAS (wild type).
In addition, the SV and copy number proﬁle of chromosome 18
was indicative of chromothripsis, with lost regions harbouring
several genes including tumour suppressor SMAD4 (Fig. 4b).
Ampliﬁcation of the oncogene KRAS and loss of tumour
suppressor SMAD4 may fuel cancer progression in this tumour.
Loss of q arm telomeric region of chromosome 18 with two
inversions suggests evidence of BFB followed by chromothripsis.
Chromothripsis has recently been associated with TP53 mutant
medulloblastoma and AML27 and it has been suggested that
chromothripsis occurs at higher frequencies in p53-deﬁcient cells.
In the present study 81% of the EACs harbour somatic TP53
point mutations and an additional 9% of the tumours contained
SV events that either inactivated TP53 or led to MDM2
gene ampliﬁcation (Supplementary Data 4 and 12). The high
frequency of TP53 inactivation in EAC, together with widespread
telomere shortening, may explain the high incidence of
chromothripsis.
Discussion
This is the ﬁrst study to report evidence of chromothripsis in EAC
and reveals that as many as a third of EAC genomes have
undergone catastrophic chromosomal events. This is a much higher
frequency than has been detected in other cancers (2–5%)25,29.
Furthermore, our data suggest that large-scale chromosomal
changes delivered by chromothripsis and BFB provide a
mechanism for tumour suppressor gene loss or oncogene
ampliﬁcation, which may then be clonally expanded due to
selective advantage, as reported in other cancer types25,28.
The observations reported here are important on two grounds.
First, they provide an explanation for the paucity of oncogenic
gain-of-function mutations identiﬁed in previous large-scale
exome studies in EAC. Although cancers like melanoma or
pancreatic adenocarcinoma are driven by point mutation of
oncogenes BRAF and KRAS, respectively, EAC appears to obtain
its oncogenic drive through ampliﬁcation. Given the genome-
wide distribution of catastrophic events seen in EAC, it is possible
that this disease has the opportunity to use a broad range of
oncogenes in transformation. Second, genomic catastrophes
provide a plausible explanation for the ability of EAC to arise
rapidly in patients, especially in those bearing BE. A catastrophe-
driven transformation from BE-EAC hypothesis is further
supported by previous studies showing that BE that progressed
to EAC present increased somatic chromosomal alterations (gains
and losses) with genomic diversity within 4 years before EAC
diagnosis2, while BE that did not progress to EAC for a long time
presented genomic stability. Telomere shortening and TP53
mutation have been reported as early genomic events in BE4,9.
These may represent a potential mechanism underlying genomic
catastrophes in EAC, since cells lacking p53 enter mitosis
prematurely with uncapped telomeres and those that persist
in mitotic p53-deﬁcient cells are shorter and prone to form
end-to-end fusions32. Further studies using WGS of longitudinal
cohorts of BE-EAC patients are required to strengthen the
ﬁndings presented here.
Finally, this study highlights the value of interrogating tumours
with a deep WGS approach when performing cancer-driver
discovery studies. Genomic catastrophes, gene inactivation
through chromosomal rearrangements and telomere integrity
appear to be important in EAC, all of which would have been
impossible to detect with exome-based cancer studies.
Methods
Samples. Samples used in this study are from patients that provided written
informed consent, with approval from the Princess Alexandra Hospital research
ethics committee (PAH-HREC-2007/068). Fresh-frozen tissue samples (snap fro-
zen in liquid nitrogen) were obtained from the Princess Alexandra Hospital
tumour bank. Clinical and pathological data were collected prospectively; tumours
were assessed by an experienced gastrointestinal pathologist (G.L.) and classiﬁed on
the basis of the current (7th) edition of the American Joint Committee on Cancer
(AJCC) staging system. For each frozen sample, a 7-mm section was used to make a
haematoxylin/eosin (H&E) slide, followed by two 30-mm sections for DNA
extraction; this was repeated to obtain a minimum of six unstained sections with
serial H&Es. The H&E slides were used to assess tumour percentage and guide
macrodissection. Samples with a minimum of 50% tumour tissue as estimated by
the pathologist were included in the study. DNA extraction was performed using
the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA, USA). DNA was quan-
tiﬁed using Qubit dsDNA BR Assay Kit (Invitrogen, Carlsbad, CA, USA). Cellu-
larity of each tumour sample was estimated using SNP array data and qpure tool12
(Supplementary Data 2).
SNP arrays and copy number analysis. Tumour and matched normal DNA was
assayed with the Omini 2.5–8, V1.0—Illumina BeadChips as per manufacturer’s
instructions (Illumina, San Diego CA, USA). SNP arrays were scanned on an iScan
(Illumina) and data were processed using the genotyping module (v1.9.4) in
GenomeStudio v2011.1 (Illumina) to calculate B-allele frequencies (BAF) and logR
ratios. GAP16 was used to call somatic regions of copy number change—gain, loss
or copy neutral LOH. SNP probes with low quality scores (GC score of o0.7) in
the matched normal sample were removed thereby suppressing germline copy
number events and probes that performed poorly. Segments were then classiﬁed as:
ampliﬁed (copy number 6–8); gained (copy number 3–5); loss (copy number 0–1)
or copy neutral LOH (copy number 2 with major allele contribution of 0 or 1).
Commonly affected genes in regions with signiﬁcant (qo0.05) gain and loss were
determined using GISTIC v2.0 (ref. 33) and genes within regions of copy number
change were annotated using ENSEMBL v70.
Whole-genome sequencing. Sequence libraries are generated from 1 mg of
genomic DNA using the standard library preparation technique using the Illumina
TruSeq DNA Sample Preparation Kit (Catalogue #: FC-121-2001), on the basis of
the protocol in the TruSeq DNA PCR-free sample preparation guide. This process
comprises pre-fragmentation cleanup using paramagnetic sample puriﬁcation
beads (Agencourt AMPureXP reagents, Beckman Coulter), sample fragmentation
and size selection targeting 300 bp inserts again by paramagnetic sample pur-
iﬁcation beads, then end-repair and ﬁnal library size quality control and quanti-
ﬁcation. Paired-end reads of 101 bp were generated in a single lane of a HiSEQ v3
ﬂowcell on the Illumina HiSEQ 2000 instrument (HiSEQ control software v1.5/
Real Time Analysis 1.13) using TruSeq SBS Kit v3-HS (200 cycles, catalogue #: FC-
401-3001). Sequencing was carried out by the Illumina Genome Network to a
minimum average of 30-fold base coverage for normal samples and 60-fold cov-
erage for tumour samples.
Mutation calling. Paired-end sequencing reads were aligned to the human gen-
ome (NCBI build37) using multi-threaded BWA34 0.6.2-mt with sorted lane level
BAMs (compressed binary version of sequence alignment/map format) created by
Samtools35 0.1.19. Whole sample level merged BAMs for tumour and matched
normal samples of each patient were produced by in-house tools and optical
duplicate reads marked using Picard MarkDuplicates 1.97 (http://
picard.sourceforge.net). These contained all mapped and unmapped data and
included pair orientation. SNVs were identiﬁed using dual calling strategy: qSNP14
which uses heuristic approach and GATK13 which is a Bayesian caller. To
maximize accuracy, SNPs identiﬁed by both callers were used as the ‘High
Conﬁdence’ calls, subsequently used in further analysis. The Pindel tool15 was used
to identify small insertions and deletions. Output ﬁltering was developed in house
to identify somatic short insertions and deletions. Examination of the context
sequence surrounding each variant was carried out, excluding indels adjacent to
homopolymer regions or near simple repeats. The remaining indels were compared
with our locally developed database of germline indels identiﬁed across diverse
cancer samples. They are also required to have supporting reads on both strands
and a minimum of 5% supporting reads from the total potential informative reads
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spanning the region. BAM ﬁles for normal and tumour samples have been
submitted to European Genome-phenome Archive (EGAS00001000750).
Mutational signature. Mutational signatures were deciphered using the frame-
work developed by Alexandrov et al.11 (http://www.mathworks.com/matlabcentral/
ﬁleexchange/38724). Mutational signatures are displayed using a 96-context
classiﬁcation deﬁned by the substitution class and the sequence context
immediately 30 and 50 to the mutated base.
Kataegis. To identify loci of localized hypermutation, termed kataegis, only high
conﬁdence somatic call (called by both GATK and qSNP) were used. For each
sample, all mutations were ordered by chromosomal position and the intermuta-
tion distances were calculated as the number of base pairs from one mutation to the
next. Intermutation distances were then segmented using piecewise constant ﬁtting
to ﬁnd regions of constant intermutation distance21. Parameters used for piecewise
constant ﬁtting were c525 and kmin52 (ref. 21). Putative regions of kataegis were
identiﬁed as those segments containing six or more consecutive mutations with an
average intermutation distance of r1,000 bp.
Structural variant analysis. Structural rearrangements were identiﬁed using the
qSV tool (http://sourceforge.net/p/adamajava/wiki/qSV/)), which uses multiple
lines of evidence to detect somatic events including discordant pairs, soft clipping
and regional de novo contig assembly of unmapped reads across potential break-
points. Calls were considered high conﬁdence when events had at least two lines of
evidence (discordant read pairs, split reads and/or soft clipping) or a single evi-
dence source with at least 10 supporting reads and no evidence observed in the
matched normal sample. Reads mapped to repeat region with high coverage
(41000) were removed from the high conﬁdence events, which were used for
further analysis. A further line of evidence was supplied by overlapping copy
number segment boundaries (SNP arrays) with breakpoint positions. Breakpoints
and copy number segments (GAP) that overlap in a range of ± 30,000 bp based
were classiﬁed as: deletions, duplications, tandem duplications, foldback inversions,
ampliﬁed inversions, inversions, intrachromosomal or translocations according to
the read pair types supporting the event together with copy number segments
(arrays). Centromeric and telomeric events (within 100 kb) and genes affected by
breakpoints were annotated using ENSEMBL v70. The likely consequence of the
rearrangement was determined from the nature of the rearrangement and the
transcription direction of affected genes.
Localized complex events. The number of SV events was estimated by qSV tool
as described above (Supplementary Data 4). The number of double strand breaks
per Mb in the genome and each chromosome were estimated for each tumour. If
one or more chromosomes presented three times more breaks per Mb than
expected and if breaks were equally distributed in the genome, they were classiﬁed
as localized complex. Evidence of clustering of breakpoints was estimated as pro-
posed by Korbel and Campbell36. Chromosomes with evidence of clustering of
breakpoints (Po0.001, Kolmogorov–Smirnov test—goodness of ﬁt test) were
reviewed for: (1) evidence of chromothripsis which included oscillation of copy
number, random joins and retention of heterozygosity and (2) evidence of BFB
which included loss of telomeric region with neighbouring highly ampliﬁed region
harbouring inversions. A larger cohort of EACs (n¼ 101) was screened for
evidence of chromothripsis using SNP arrays (Illumina), chromothripsis was
inferred in cases where one or few chromosomes showed at least 10 switches in
copy number states, with retention of heterozygosity.
Veriﬁcation of somatic mutations. Primers for somatic indels (n¼ 188) were
designed using qAmplicon (http://sourceforge.net/p/adamajava/wiki/qAmplicon/).
We were able to design primer for 179 indels. PCRs were performed for tumour
and matched normal pairs. PCR products were pooled by patient and tissue type.
Each pool was then diluted in DNase/RNase-free water to a ﬁnal concentration of
0.2 ng ml, then barcoded libraries were prepared for each pool using the Illumina
Nextera XT DNA Sample Preparation Kit. Libraries were quantiﬁed on the Perkin
Elmer LabChip GX, normalized and pooled together in equimolar ratio. The library
pool was diluted and denatured according to the standard MiSeq protocol, and
11 pM was loaded for sequencing on a 2 301 bp run on the Illumina MiSeq using
the 600 cycle MiSeq Reagent Kit v3. MiSeq data were mapped using BWA-MEM,
and tumour and matched normal BAMs were manually reviewed in IGV. A total of
166 indels had sequence coverage 4200 for tumour and normal sample (those
were considered testable) with a veriﬁcation rate of 95%.
HiSeq X Ten data of a re-sequenced tumour matched normal pair
(OESO_0384) was used for SNP veriﬁcation. Sequencing was performed by the
Garvan Center for Clinical Genomics using 100 ng of DNA and eight cycles of
PCR. Fastq ﬁles were mapped with BWA-MEM. Substitutions were called veriﬁed
if evidence of the somatic event was observed in the XTen data. A total of 5,480
SNPs were tested with a veriﬁcation rate of 99.56%.
Structural variants suspected to be involved in DM formation were veriﬁed by
PCR across the rearrangement’s breakpoint and conﬁrmed by gel electrophoresis.
A total of six events were validated for inferred DM on patient OESO_3212 and
ﬁve events for OESO_0384 DM. PCR primers were designed using qAmplicon to
span the predicted breakpoint. PCR reactions were carried out in the tumour and
matched normal genomic DNA using a 25 ml reaction composed of 22ml of
Platinum Taq DNA polymerase (Invitrogen), 2 ml of 10 mM primer (Integrated
DNA Technology) and 1 ml of genomic DNA as template (1 ngml). The following
parameters were used for PCR; initial denaturation at 94 C for 2min; followed by
35 cycles: denaturation at 94 C 30 s; annealing at 60 C 30 s; extension at 68 C
1min; followed by ﬁnal extension at 68 C for 15min. PCR products were
visualized by gel electrophoresis and if a PCR band of the expected size was
observed only in the tumour and not in the normal, the somatic event was
considered veriﬁed.
Assessment of telomeric DNA content. Reads containing the telomeric repeat
(50-TTAGGG-30) 3 or (50-CCCTAA-30) 3 were counted and normalized to the
average genomic coverage (the average base coverage of each genome). The nor-
malized telomere count was obtained separately for each tumour and its matching
normal. Ratio was calculated by tumour normalized counts/normal normalized
counts.
Fluorescent in situ hybridization. Frozen sections of tumour OESO_0384 and
OESO_3213 were cut in a cryostat at 5 mm thickness. Sections were ﬁxed in ice cold
100% methanol for 2-1/2min and air dried. Probes were applied to sections (0.5 ml
of each probe in 5 ml hybridisation buffer, Empire Genomics) under coverslips.
Probes were denatured at 83 C for 3min and incubated in a humid slide chamber
overnight (B16 h) at 37 C. Sections were washed as follows: 2min at 73 C in
0.4 SSC/0.3% IGEPAL followed by 1min at room temp in 2 SSC/0.1%
IGEPAL followed by three rinses in water. Slides were mounted in 0.2mgml
40,6-diamidino-2-phenylindole in Prolong Gold Antifade reagent (Life Techno-
logies). Slides were visualized using a Zeiss Axio Fluorescence microscope and
images were captured using Applied Imaging Cytovision software (Applied
Imaging International) on an Olympus BX51 Fluorescence microscope.
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